Welcome to our dedicated page for Tg Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on Tg Therapeutics stock.
Overview of TG Therapeutics Inc
TG Therapeutics Inc (NASDAQ: TGTX) is a specialized biopharmaceutical company dedicated to the acquisition, development, and commercialization of innovative therapies for B-cell diseases, including hematologic malignancies and autoimmune disorders. The company leverages advanced technologies such as glycoengineering to create optimized monoclonal antibodies that target critical cellular antigens and signaling pathways. Key products under development incorporate deep scientific insights into B-cell biology and have been designed to improve patient outcomes by providing more efficient and targeted treatments.
Core Therapeutic Areas and Pipeline Focus
TG Therapeutics is at the forefront of developing therapies targeting B-cell malignancies and autoimmune conditions. Its leading candidate, a glycoengineered monoclonal antibody designated TG-1101 (also known by its commercial name BRIUMVI), is engineered to target a unique epitope on the CD20 antigen. This specificity aids in the efficient depletion of mature B-lymphocytes, a critical aspect in the treatment of relapsing forms of multiple sclerosis (RMS) and potentially other autoimmune disorders. Additionally, the company is advancing TG-1202, an orally available PI3K delta inhibitor, to address the proliferation and survival of B-cells, particularly in the realm of hematologic disorders.
Development Strategy and Commercial Operations
Operating as a fully integrated commercial stage company, TG Therapeutics actively manages a diverse portfolio that spans late-stage clinical trials to preclinical research. Their robust pipeline is designed to address unmet medical needs in critical patient segments. Emphasizing both rigorous clinical development and strategic commercialization, the company has secured approvals in key markets and is expanding its footprint via collaborations and a dedicated infrastructure to ensure effective market delivery. The company also pursues additional targets, including inhibitors aimed at modulating key inflammatory pathways, thereby reinforcing its commitment to innovation.
Industry Position and Competitive Landscape
TG Therapeutics differentiates itself through a deep expertise in antibody engineering and a focus on novel mechanisms of action. By addressing the challenges inherent in B-cell targeted therapies and autoimmune treatments, the company competes with other biopharmaceutical firms by demonstrating a detailed understanding of immune modulation. Its clinical development programs, backed by comprehensive research and regulatory milestones, position it as a valuable and insightful contributor in the competitive biotechnology arena.
Commitment to Scientific Excellence and Transparency
The company's scientific approach is characterized by a clear, data-driven evaluation of its therapeutic candidates and a commitment to continual improvement. Transparent reporting of clinical trial designs, outcomes, and safety profiles underpins its reputation for expertise and trustworthiness. TG Therapeutics provides comprehensive information that aids healthcare professionals, researchers, and investors in understanding its innovative approach and detailed product profiles without resorting to speculative claims.
Conclusion
For professionals seeking an in-depth understanding of a biopharmaceutical company driven by novel research in B-cell diseases, TG Therapeutics offers a wealth of expertise. Its strategic focus on integrating cutting-edge science with efficient commercialization practices makes it an important entity in the evolving landscape of treatments for hematologic malignancies and autoimmune disorders.
TG Therapeutics (TGTX) announced that both ULTIMATE I & II Phase 3 trials of ublituximab met their primary endpoints, demonstrating a statistically significant reduction in annualized relapse rate (ARR) over 96 weeks (p<0.005). The findings will be presented at the ECTRIMS Congress on October 14, 2021. The trials involved 1,094 patients across 10 countries. Ublituximab, an investigational treatment, targets CD20+ B-cells and aims to improve outcomes for patients with relapsing multiple sclerosis (RMS). An investor event will discuss the trial data at 12:30 PM ET on the same day.
TG Therapeutics announced the publication of safety results for UKONIQ® (umbralisib) in patients with relapsed lymphoid malignancies. The study, published in Blood Advances, included data from 371 patients, highlighting a low discontinuation rate due to adverse events, suggesting a favorable safety profile. UKONIQ is the first dual inhibitor of PI3K-delta and CK1-epsilon, now available for treating marginal zone and follicular lymphoma. The company aims for FDA approval of a combination treatment with ublituximab by March 25, 2022.
TG Therapeutics to Participate in Healthcare Conference
TG Therapeutics (NASDAQ: TGTX) announced that CEO Michael S. Weiss will join a fireside chat at the 2021 Cantor Virtual Healthcare Conference on September 27, 2021, at 10:40 AM ET. The conference runs from September 27 to 30, 2021. A live webcast will be available on the company's Events page, with a replay following the event. TG Therapeutics focuses on innovative treatments for B-cell malignancies and autoimmune diseases and has received FDA accelerated approval for UKONIQ®.
TG Therapeutics (NASDAQ: TGTX) announced a virtual event on September 20, 2021, at 8:30 AM ET to discuss updated data from their Phase 1 trial of U2 (umbralisib and ublituximab) combined with venetoclax for treating chronic lymphocytic leukemia (CLL). Highlights from the XIX International Workshop on Chronic Lymphocytic Leukemia were shared, demonstrating significant improvements in progression-free survival (PFS) and overall response rates (ORR) in these combinations. A PDUFA date for potential U2 regimen approval is set for March 25, 2022.
TG Therapeutics is set to host a virtual investor and analyst event on September 20, 2021, at 8:30 AM ET to discuss updated Phase 1 data for the combination of UKONIQ® (umbralisib) and ublituximab (U2) with venetoclax. This follows significant findings presented at the XIX International Workshop on Chronic Lymphocytic Leukemia with a reported 100% overall response rate among 46 patients with relapsed or refractory CLL. The event will also cover the ULTRA-V Phase 2/3 trial, highlighting the promising efficacy of the investigational treatment.
TG Therapeutics (NASDAQ: TGTX) announced that CEO Michael S. Weiss will participate in a fireside chat during the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The chat will be available for on-demand download starting at 7:00 AM ET on September 13, 2021, on the company's website. TG Therapeutics focuses on developing treatments for B-cell malignancies and autoimmune diseases, with several investigational medicines in various phases of clinical development.
TG Therapeutics, Inc. (NASDAQ: TGTX) announced four data presentations at the virtual XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL) from September 17 to 20, 2021. Key highlights include the Phase 3 UNITY-CLL study showing the superiority of its U2 therapy over competitors in treatment-naïve and relapsed forms of Chronic Lymphocytic Leukemia (CLL). Additionally, updated Phase 1 results of a triple combination therapy will be shared, which has led to the initiation of the ULTRA-V Phase 2/3 trial. The PDUFA date for U2 is March 25, 2022.
TG Therapeutics (TGTX) reported its Q2 2021 financial results, announcing net product revenue of $2.3M from UKONIQ, launched for specific lymphoma treatments. The FDA accepted a BLA and sNDA for the combination treatment (U2) targeting CLL, with a PDUFA date set for March 25, 2022. R&D expenses rose to $44.9M, largely due to milestone fees, while total SG&A expenses reached $34M. The net loss for the quarter was $78.5M. The company's cash position stood at $456.2M, expected to support operations into 2023.
TG Therapeutics (TGTX) announced a conference call on August 2, 2021, at 8:30 AM ET to discuss its second-quarter 2021 results and provide a business outlook. The call will be led by CEO Michael S. Weiss. Participants can join via phone or through a live webcast on the company's website. A financial results press release will precede the call. TG Therapeutics is focused on developing therapies for B-cell malignancies and autoimmune diseases, with significant advancements including FDA approval for UKONIQ® and ongoing Phase 3 programs.
TG Therapeutics, Inc. (NASDAQ: TGTX) announced that Michael S. Weiss, Chairman and CEO, will engage in a fireside chat at the Ladenburg Thalmann 2021 Healthcare Conference on July 14, 2021, at 12:30 PM ET. The event will be held virtually, and a live webcast will be available on the company's Events page. TG Therapeutics specializes in developing treatments for B-cell malignancies and autoimmune diseases and has received FDA accelerated approval for UKONIQ™.
FAQ
What is the current stock price of Tg Therapeutics (TGTX)?
What is the market cap of Tg Therapeutics (TGTX)?
What is TG Therapeutics Inc's primary focus?
What is unique about their lead product candidate?
Which therapeutic areas does TG Therapeutics primarily target?
How does TG Therapeutics differentiate itself from competitors?
What other products or technologies are in the company’s pipeline?
Where is TG Therapeutics headquartered and traded?
What role do clinical trials play in TG Therapeutics' strategy?
How does TG Therapeutics enhance trust and transparency?
